The TRC8 gene, which was previously shown to be disrupted by a 3;8 chromosomal translocation in hereditary kidney cancer, encodes for an endoplasmic reticulum-resident E3 ligase. Studies have shown that TRC8 exhibits a tumor-suppressive effect through its E3-ligase activity. Therefore, the identification of its physiological substrates will provide important insights into the molecular mechanism underlying TRC8-mediated tumor suppression. Here we show that TRC8 targets heme oxygenase-1 (HO-1) , an antioxidant enzyme highly expressed in various cancers, for ubiquitination and degradation. Ectopic TRC8 expression suppresses HO-1-induced cancer cell growth and migration/invasion. Conversely, HO-1 depletion reduced the tumorigenic and invasive capacities promoted by TRC8 knockdown. HO-1 downregulation in renal carcinoma cells induces a mitotic delay at G2/M phase by increasing the intracellular reactive oxygen species and the DNA-damage-induced checkpoint activation. These results highlight the tumorigenic role of HO-1 and the importance of TRC8-mediated HO-1 degradation in the control of cancer growth.
INTRODUCTION
The TRC8 gene (translocation in renal carcinoma, chromosome 8 gene), also known as RNF139 (ring-finger protein 139) gene, was first identified from a family with 3;8 chromosomal translocation and hereditary renal cell carcinoma and thyroid cancer. 1 The disruption of TRC8 gene was later reported in the sporadic cases of renal cancer and ovarian dysgerminoma. 2, 3 It encodes an endoplasmic reticulum (ER)-resident protein with 10 transmembrane segments (TMSs). 1 The amino-acid sequence reveals that TRC8 contains a sterol-sensing domain similar to that identified in HMG-CoA reductase and the sterol regulatory elementbinding protein cleavage activating protein in the N-terminal region and a RING-H2 domain with E3-ligase activity in the C-terminus. An early study in Drosophila has demonstrated that the Drosophila TRC8 homologue, DTrc8, directly interacts with DVhl and CSN-5/JAB1 and functions with DVhl in a common pathway to affect midline development. 4 Subsequently, a study in HEK293 cells has revealed that overexpression of wild-type TRC8, but not the RING mutants, promotes the growth arrest in G2/M phase, which is associated with the activation of ATM and Chk2. 5 However, the mechanism underlying TRC8-induced checkpointkinase activation has remained elusive. TRC8 also inhibits tumor growth in nude mice in a RING-dependent manner, 5 supporting the importance of the E3-ligase activity in mediating its tumorsuppressor function. Identification of the physiological substrates of TRC8 is apparently crucial to understanding the mechanism of TRC8-mediated tumor suppression.
Heme oxygenase-1 (HO-1) is a rate-limiting enzyme catalyzing the oxidative degradation of heme to free iron, carbon monoxide and biliverdin. 6 It is highly induced in various pathophysiological states associated with oxidative stress, including cancers. 7 Numerous studies have revealed that HO-1 induction represents an important cytoprotective defense response against various insults through the antioxidant capacities of biliverdin and its metabolite, bilirubin, as well as the anti-inflammatory effect of carbon monoxide. 6 Forced expression of HO-1 in cancer cells has been shown to promote tumor growth and an angiogenic response in vitro and in vivo. [8] [9] [10] Moreover, HO-1 is implicated in the resistance of cancer cells to apoptosis induced by chemotoxic agents and irradiation. [11] [12] [13] Inhibition of HO-1 expression overcomes the resistance of chronic myeloid leukemia and pancreatic cancer cells to chemotherapeutic agents and inhibits the growth of hepatocellular carcinoma and hormone-refractory prostate cancer in vivo. [14] [15] [16] [17] These findings suggest that HO-1 is a potential target for cancer treatment.
Substantial work has been carried out to understand how HO-1 expression is regulated, particularly at the transcriptional level. [18] [19] [20] [21] [22] [23] [24] However, its regulation at the posttranslational level remains largely unknown. Recently, we demonstrated that HO-1, which is anchored in the ER through its C-terminal TMS, undergoes ubiquitination and proteasome-mediated degradation through an ER-associated degradation pathway. 25 In an attempt to identify the E3 ligase that mediates HO-1 ubiquitination, in the present study, we performed a screening assay using a full-length cDNA array containing genes related to protein ubiquitination. This approach allowed us to identify TRC8 as the E3 ligase responsible for HO-1 ubiquitination and degradation. Moreover, the tumor-suppressive effect of TRC8 is mediated, at least in part, through downregulation of HO-1.
RESULTS

TRC8 facilitates HO-1 protein turnover
To identify the E3 responsible for HO-1 ubiquitination, we performed a screening assay using a full-length cDNA array containing 352 genes related to protein ubiquitination. As illustrated in Figure 1a , the yellow fluorescent protein (YFP)-tagged HO-1 cDNA construct and each cDNA clone on the arrays were cotransfected into HEK293T cells on 96-well plates, followed by cycloheximide (CHX) treatment and the decay of the YFP fluorescence in each well monitored and compared with that of control cells transfected only with YFP-HO-1 cDNA construct. Using this approach, we identified a cDNA clone encoding TRC8, which facilitated YFP-HO-1 decline in the presence of CHX. Western blot analysis confirmed that TRC8 downregulated HO-1 protein expression in a dose-dependent manner (Figure 1b) . TRC8 overexpression did not affect the level of HO-1 mRNA (Supplementary Figure 1) , indicating that the effect of TRC8 is at HO-1 protein level. Moreover, TRC8-induced downregulation of HO-1 protein expression was attenuated by cotreatment of cells with the proteasome inhibitor MG132 (Figures 1b and c) . TRC8 had no effect on YFP protein expression (Figure 1c) , indicating that the effect of TRC8 on YFP-HO-1 is specific. CHX chase experiment showed that TRC8 overexpression significantly reduced the half-life of HO-1 coexpressed in HeLa cells (Figure 1d) . We also performed a CHX chase experiment using U2OS cells stably expressing short hairpin RNA (shRNA) targeting TRC8 (sh-TRC8). Western blot analysis revealed that the TRC8 expression was reduced by B75% in cells expressing sh-TRC8 (Figure 1e ). Moreover, the turnover rate of endogenous HO-1 induced by cobalt protoporphyrin IX treatment was much lower in TRC8-knockdown cells than in the controls expressing a negative-control shRNA (sh-Ctl) (Figure 1e ).
TRC8 promotes HO-1 protein ubiquitination As shown in Figure 2a , overexpression of wild-type TRC8 increased the ubiquitination of His-tagged HO-1 expressed in HEK293T cells. Whereas, HO-1 ubiquitination was not significantly affected by overexpressing a TRC8 mutant with mutations in RING domain (C547A and C550A), which has been shown to ablate E3-ligase activity.
5 TRC8-mediated HO-1 ubiquitination was not seen in cells expressing a His-tagged truncated HO-1 (t-HO-1) lacking C-terminal 24 amino acids containing the TMS (Figure 2b ). Confocal immunofluorescence experiment revealed that t-HO-1, which exhibits cytosolic and nuclear distribution, 26 did not colocalize with TRC8 in the ER (Supplementary Figure 2) . Moreover, overexpressions of AMFR and SYVN1, the other two mammalian ER-associated E3 ligases mediating the degradation of several ER-resident proteins, 27 had no effect on HO-1 ubiquitination (Figure 2c ). To demonstrate that HO-1 is a direct substrate of TRC8, we also performed in vitro ubiquitination by incubating purified glutathione S-transferase or glutathione S-transferase-fused HO-1 protein with ubiquitin, ATP, E1, E2 (UbcH5b) and immunoprecipitated hemagglutinin (HA)-tagged TRC8 at 30 1C for 2 h, followed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and western blot analysis. As shown in Supplementary Figure 3 , the high molecular weight ubiquitinated species were detected in the reaction containing glutathione S-transferase-fused HO-1 but not glutathione S-transferase protein. Moreover, the ubiquitinated products were not detected in the reaction omitting TRC8 or E1/E2.
Interaction between TRC8 and HO-1 We next examined the interaction between TRC8 and HO-1. HEK293T cells were cotransfected with a HA-tagged TRC8 construct and a Flag-tagged HO-1 or t-HO-1 construct, then cell lysates were immunoprecipitated with anti-Flag affinity gel. Western blot analysis of the immunoprecipitates with anti-HA antibody revealed that HA-tagged TRC8 was co-immunoprecipitated with the full-length HO-1, but not the t-HO-1 (Figure 3b) . Conversely, when HA-tagged TRC8 was immunoprecipitated with anti-HA affinity gel, followed by western blot analysis of the immunoprecipitates with anti-Flag antibody, only full-length HO-1 was detected again (Figure 3c ). As TRC8 contains 10 TMSs, we then performed co-immunoprecipitation experiments using a series of HA-tagged TRC8 C-terminal truncation constructs containing various numbers of TMSs (Figure 3a) to dissect which TMS is potentially involved in the interaction with HO-1. As shown in Figure 3d , removal of the RING domain and TMSs X-VIII of TRC8 and the region up to residue 316 (HA-T-316), just C-terminal to TMSVII, did not affect the interaction with HO-1. However, further removal of TMSVII abolished the interaction. We also performed the co-immunoprecipitation with a construct (HA-T-316 D211-270 ) lacking TMSs X-VIII and the amino-acid residues 211-270 within the loop region between TMSVI and TMSVII. The result showed that this deletion construct again failed to interact with HO-1. (Figure 4f ) of HeLa cells, and these effects were abolished by TRC8 overexpression, which had little effect on the mock cells. We then performed experiments to assess whether TRC8 downregulation has an effect on cancer cells. Two U2OS cell lines with stable TRC8 knockdown mediated by two different specific shRNAs targeting TRC8 (sh-TRC8-1 and sh-TRC8-2) were established. As shown in Figures 5a and b, TRC8 expression was reduced by over 75% in these two TRC8-knockdown cell lines. Correspondingly, HO-1 levels were markedly increased in TRC8-depleted cell lines, which correlated with increased cell HO-1 downregulation promotes oxidative stress and checkpoint activation As HO-1 is an antioxidant enzyme, we then examined the potential involvement of oxidative stress in this process. As demonstrated in Figures 7a and b , the intracellular level of reactive oxygen species detected by a redox-sensitive fluorescent dye, 5-(and-6)-chloromethyl-2 0 ,7 0 -dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA), was significantly higher in both HO-1-knockdown cell lines as compared with control cells. The DNA damage as measured by the 8-hydroxy-2-deoxyguanosine level was also much higher in both HO-1-knockdown cell lines (Figure 7c ). To investigate whether the increased DNA damage causes checkpoint activation, which leads to the mitotic delay, we examined the phsophoryation states of Chk1 and Chk2 proteins. As shown in Figure 7d , the phosphorylation of Chk1, but not Chk2, was significantly increased in HO-1-knockdown cells. This was correlated with the increase in the phosphorylation of CDC25C, the substrate of Chk1, in the HO-1-knockdown cells (Figure 7d ). On the other hand, HO-1 downregulation did not significantly affect the levels of cyclin B and CDC2. To confirm the role of reactive oxygen species in the checkpoint activation, we cultured cells in the complete medium containing 2 mM N-acetylcysteine. As shown in Figure 7e , the proliferation rates of the control and HO-1-knockdown cells were comparable. Likewise, Figure 2 . TRC8 promotes HO-1 ubiquitination. (a) HEK293T cells were transfected for 24 h with HA-tagged ubiquitin cDNA (HA-Ub) alone or together with His-tagged HO-1 cDNA (His-HO-1) alone or together with wild-type TRC8 cDNA (Wt-TRC8) or mutant TRC8 cDNA (Mu-TRC8) as indicated, then His-HO-1 protein was isolated by metal affinity resin and subjected to western blot analysis with antibodies against the HA tag (top panel) or HO-1 (middle panel). Expression of HO-1, TRC8 or b-actin (internal control) in whole-cell lysates (WCLs) was also examined by western blot analysis (bottom panel). (b) HEK293T cells were transfected with TRC8 cDNA alone or together with HA-Ub cDNA and cDNA encoding either His-tagged HO-1 or His-tagged truncated HO-1 lacking the C-terminal 24 residues (His-t-HO-1). After 24 h, the cells were lysed and His-tagged HO-1 or the truncated HO-1 isolated and subjected to western blot analysis with antibodies against the HA tag (top panel) or HO-1 (bottom panel). (c) HEK293T cells were transfected for 24 h with HA-Ub cDNA and His-HO-1cDNA with or without cDNA encoding TRC8, AMFR or SYVN1 as indicated, then His-HO-1 was isolated and subjected to western blot analysis as described above (top and middle panels). Expression of TRC8, AMFR and SYVN1 in the WCL was also examined by western blot analysis using specific antibodies (bottom panel).
the phosphorylation states of Chk1 and CDC25C examined after 2 days of N-acetylcysteine treatment did not show significant difference between the control and HO-1-knockdown cells (Figure 7f ).
DISCUSSION
TRC8 is an ER-associated E3 ligase with tumor-suppressor function.
A recent study demonstrated that TRC8 targets MHC class I molecules for ubiquitination and degradation in cells expressing cytomegalovirus protein US2. 28 The downregulation of cell-surface expression of MHC class I molecules might be expected to favor tumor growth by escape from immune attack, rather than explain the suppressive effect of TRC8 on tumor growth. Other studies have shown that TRC8 overexpression can downregulate genes involved in cholesterol and fatty-acid biosynthesis by stimulating the destabilization of the ER-bound sterol regulatory elementbinding proteins 29 and hindering ER to Golgi transport of sterol regulatory element-binding protein-2. 30 Moreover, TRC8 induction suppresses protein translation by interacting with eIF3, a component of the translation initiation complex. 29 The impacts on lipid and protein biosynthesis may contribute to the effect of TRC8 on tumor growth. However, other mechanisms are likely involved and await further investigation.
In this report, we demonstrate that HO-1 is a physiological substrate of TRC8. HO-1 lacking its single C-terminal TMS cannot be ubiquitinated and co-immunoprecipitated by TRC8, suggesting that the TMS of HO-1 is likely involved in the interaction of HO-1 with TRC8. The co-immunoprecipitation experiments using a series of C-terminal-truncated TRC8 proteins demonstrated that the removal of TMSVII of TRC8 completely prevented the interaction with HO-1, suggesting that the binding of TRC8 to HO-1 requires the interaction between the TMSVII of TRC8 and likely the TMS of HO-1. Further experiment demonstrated that the truncation of the loop region between TMSVI and TMSVII of TRC8 also abolished the interaction between TRC8 and HO-1. This result may argue that the effect of TMSVII truncation is attributed to its influence on the structure of this adjacent loop. However, TRC8 fails to interact with t-HO-1, indicating that the loop alone is not sufficient to mediate the binding of TRC8 to HO-1. It appears that both TMSVII and the loop between TMSVI and TMSVII are required for TRC8 to form stable interaction with HO-1 in the ER. Because the N-terminal-truncated TRC8 protein could not be successfully expressed for co-immunoprecipitation experiment, the possible involvement of the TMS I-VI cannot be completely ruled out. Furthermore, whether other protein partners are engaged in the interaction between HO-1 and TRC8 remains to be clarified.
Consistent with earlier findings that HO-1 promotes proliferation and invasion of various cancer cells, 10,16,17,31-34 ectopic expression of HO-1 in HeLa cells promotes cell proliferation and migration/invasion. Notably, TRC8 overexpression suppressed cell proliferation not only in HO-1-overexpressing HeLa cells but also in mock cells, suggesting that TRC8 may inhibit cell proliferation through both the HO-1-dependent and -independent pathways. Moreover, TRC8 overexpression abolished the enhanced migration/invasion observed in HO-1-overexpressing HeLa cells without significantly affecting the migration/invasion of mock cells. These observations support that TRC8 can downregulate the tumorigenic effects of HO-1. The reciprocal roles of TRC8 and HO-1 were further demonstrated in experiments showing that the cell proliferation and migration/invasion were significantly enhanced in U2OS cells with TRC8 knockdown. When the elevated HO-1 in TRC8-knockdown U2OS cells was downregulated by specific siRNA targeting HO-1, it substantially inhibited the increase in cell growth and migration/invasion promoted by TRC8 depletion, indicating that the increased HO-1 levels contribute to the increased aggressiveness of the TRC8-knockdown cells. Taken together, our data provide the evidence to support the idea that TRC8 induces tumor suppression, at least in part, through downregulation of HO-1.
HO-1 overexpression is seen in many cancers, including renal cell carcinoma. [35] [36] [37] TRC8 has been shown to induce G2/M arrest in HEK293 cells, 5 although the underlying mechanism has not been explored. To increase our understanding on the tumorigenic effect of HO-1, we examined the impact of HO-1 downregulation on the cell-cycle progression of A498 renal carcinoma cells, which express high level of HO-1. Our results showed that HO-1 downregulation causes a mitotic delay at G2/M phase via augmenting DNA damage and Chk1-mediated checkpoint activation in A498 cells. These observations highlight the importance of HO-1-regulated redox on cell-cycle checkpoint control in cancer cells. A recent study showed that the antioxidant program induced by Nrf2 transcriptional factor promotes cell transformation and tumorigenesis. 38 As HO-1 is one of the target genes regulated by Nrf2, it is conceivable that HO-1-mediated antioxidant response may contribute to the tumorigenic process. Nevertheless, a study by Otterbein et al. 39 demonstrated that HO-1 deficiency causes accelerated DNA damage and impaired DNA repair in normal cells following genotoxic insults, implicating that the low expression of HO-1 may promote the initiation of tumor formation by increasing the rate of cancer-causing mutations. It appears that HO-1 may have contradictory roles in the different stages of cancer development. In fact, studies have found many genes that can exert dual functions in cancer. [40] [41] [42] [43] As tumorigenesis is a complex process, it will be of great interest to learn whether or not TRC8 may also function as a tumor promoter in certain cell contexts.
In summary, our study has revealed a new mechanism by which TRC8 suppresses tumor progression through targeting HO-1 for degradation. Although the activation of gene transcription contributes to the upregulation of HO-1 in many cancers, 9,14,37,44 the dysfunction or downregulation of TRC8 can add another layer of regulation of HO-1 at the posttranslational level in this disease state.
MATERIALS AND METHODS Plasmids
The ubiquitin genome-wide full-length cDNA (GFC)-transfection array and plasmids containing human TRC8, AMFR or SYVN1 cDNA were obtained from OriGene (Rockville, MD, USA). N-terminal Flag-tagged full-length HO-1 and C-terminal 24 amino-acid-truncated HO-1 cDNA constructs were prepared by subcloning the respective cDNA 26 into the Flag-CMV (Hygro-R) expression vector. N-terminal His-tagged full-length and C-terminaltruncated HO-1 cDNAs were subcloned into the pcDNA3.1/HisC vector (Invitrogen, Grand Island, NY, USA). N-terminal HA-tagged full-length TRC8 cDNA and the series of C-terminal-truncated TRC8 cDNAs were subcloned into the pcDNA-HA2 vector. The TRC8 (C547A and C550A) mutant construct was generated by site-directed mutagenesis using PCR. TRC8-specific shRNAs (target sequence no. 
Ubiquitin GFC-transfection array screening
The screening with the ubiquitin GFC-transfection arrays in 96-well plates was performed according to the manufacturer's instruction with some modifications. Briefly, YFP or YFP-tagged HO-1 plasmid DNA 27 (25 ng) and the Effectene transfection reagent (Qiagen, Venlo, Netherlands, French) was added into each individual well containing 100 ng of an ubiquitinassociated cDNA clone. After incubation for 10 min at room temperature, 1.5 Â 10 4 HEK293T cells in 100 ml of Dulbecco's modified Eagle's medium containing 10% FBS were plated into each well and incubated at 37 1C in a humidified CO 2 incubator. Twenty-four hours after transfection, cells were treated with CHX (20 mM) and fluorescence was measured by Typhoon 9410 Variable Mode Imager (Amersham BioSciences, Piscataway, NJ, USA) at 0, 6, 12 and 18 h after drug treatment. The intensity of fluorescence was analyzed by MetaMorph image analysis software (Molecular Devices, Silicon Valley, CA, USA).
Cell culture and plasmid transfection HEK293T and HeLa cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. A498 cells were cultured in minimum essential medium eagle supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids and antibiotics as above. U2OS cells were cultured in McCoy's 5A medium supplemented with 10% FBS and antibiotics as above. For plasmid-transfection experiments, Effectene reagent (Qiagen) was used for transfection of HEK293T or HeLa cells and Lipofectamine 2000 (Invitrogen) for transfection of U2OS and A498 cells.
Stable cell line establishment
HeLa cells were transfected with control vector or Flag-tagged HO-1 vector and treated with hygromycin (400 mg/ml) to select colonies. U2OS cells were transfected with pLKO.1-Puro vector bearing control shRNA or shRNA targeting TRC8 and selected with puromycin (2 mg/ml). A498 cells were transfected with pLKO.1-Puro vector bearing control shRNA or shRNA targeting HO-1 and selected with puromycin (3 mg/ml). Stable colonies derived from the same plasmid transfection were pooled and expanded for further experiments. siRNA-mediated HO-1 knockdown U2OS cells stably expressing control shRNA or TRC8-specific shRNA were seeded in 6-cm dishes at a density of 3.5 Â 10 5 per dish and transfected with 50 pmol of control scrambled siRNA (sc-37007; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or specific siRNA targeting HO-1 (sc-44306; Santa Cruz Biotechnology) by Lipofectamine 2000 according to the manufacturer's instruction. After transfection for 6 h, the medium was replaced once with culture medium containing 10% FBS. At 24 h, cells were trypsinized and replated in 10-cm dishes and allowed to grow for an additional 24 h. Cells were then detached and used for subsequent experiments as indicated.
In vivo ubiquitination assay HEK293T cells were cotransfected with the indicated combinations of the His-tagged HO-1 plasmid, the HA-tagged ubiquitin plasmid, and an E3-ligase plasmid for 30 h, then the cells were lysed, and His-tagged HO-1 isolated by metal affinity resin and subjected to western blot analysis using anti-HA antibody.
Western blot analysis
Western blot analysis was performed as described previously. 25 The primary antibodies used were anti-HO-1 (1:2000), 25 anti-TRC8 (Abcam, Cambridge, MA, USA; 1:3000), anti-AMFR (Sigma, St Louis, MO, USA; 
Immunoprecipitation
HEK293T cells were transfected for 24 h with Flag-tagged HO-1 construct with or without HA-tagged full-length TRC8 or various C-terminaltruncated TRC8 constructs, then cells were lysed with buffer A (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA and a protease inhibitor mixture) containing 0.5% NP-40 and the lysate centrifuged at 13 000 g for 15 min at 4 1C. The supernatant was removed and diluted five-fold with buffer A, then 400 mg of protein was incubated for 4 h at 4 1C with 20 ml of anti-HA affinity gel (Sigma) or ANTI-FLAG M2 affinity gel (Sigma), then the gel was washed four times with buffer A containing 0.1% NP-40 and bound proteins were eluted using 2 Â sodium dodecyl sulfate sample buffer.
Cell-proliferation assay
Cells were seeded in 12-well plates at the indicated density and cultured in complete medium. The culture medium was replaced with fresh medium 
Migration and invasion assays
The cell-migration assay was performed using a 24-well transwell plate (8-mm pore polycarbonate membrane insert; Corning, Corning, NY, USA). To assess cell invasion, the BD BioCoat Matrigel invasion chamber (BD Biosciences, Franklin Lakes, NJ, USA) was used for the migration assay. Briefly, cells were seeded in the upper chamber in serum-free medium, and the bottom chamber was filled with complete medium containing 10% FBS as chemoattractant. After incubation for 24 h (migration) or 48 h (invasion), cells remaining in the upper chamber were removed by cotton swab. Cells on the lower surface of membrane were stained with 0.5% crystal violet for 10 min and photographed with stereomicroscope using Â 10 occur lens and Â 0.8 object lens (Lumar V.12; Zeiss, Thornwood, NY, USA). Cells in five random fields were counted and averaged using MetaMorph Offline software.
Cell-cycle analysis
For synchronization, cells (1.5 Â 10 5 ) were seeded in 10-cm dishes with 10% FBS complete medium. The next day, cells with 50% confluence were treated with 2 mM thymidine for 16 h. Cells were then washed twice with Hanks' buffered saline solution, refeeded with 10% FBS complete medium. After 8 h incubation, cells were retreated with 2 mM thymidine for 16 h to synchronize cells at G1/S boundary. After two washes with HBSS, 10% FBS medium was added back into culture and cells were collected at various time points as indicated. For cell-cycle analysis, cells were fixed in 70% ethanol and treated with 0.2 mg/ml RNAse A (Fermentas, Hanover, MD, USA) for 30 min. DNA was stained with 20 mg/ml propidium iodide (Invitrogen) in the presence of 0.1% Triton X-100 at 4 1C for 15 min and analyzed with FACScan (Becton Dickinson, Franklin Lakes, NJ, USA). Data were acquired using BD CellQuest software and processed with the ModFit LT software (Verity Software House, Topsham, ME, USA). To determine the mitotic index, cells releasing from double-thymidine block for 12 h were collected and swollen with 0.5 Â ice-cold phosphate-buffered saline for 10 min on ice. After centrifugation at 500 g for 5 min at room temperature, cells were resuspended in ethanol/acetic acid (3:1 v/v) and vortexed gently to obtain a final concentration of 1-5 Â 10 3 cells/ml. Dropped B100 ml of cells to glass slide and cells were stained with 4 0 -6-diamidino-2-phenylindole. Mitotic index was determined by scoring about 1000 cells under a fluorescent microscope (TH4-100; Olympus, Tokyo, Japan).
Intracellular reactive oxygen species measurement
The intracellular reactive oxygen species was detected using the fluorescent probe CM-H2DCFDA (Molecular Probes, Eugene, OR, USA). Briefly, cells were loaded with 10 mM CM-H2DCFDA in the dark for 1 h at 37 1C. Cells were washed once with phosphate-buffered saline, incubated in prewarmed growth medium for additional 30 min at 37 1C, trypsinized and analyzed with the fluorescence-activated cell sorting as described above.
8-hydroxy-2-deoxyguanosine determination
The level of DNA damage was determined using the oxidative DNAdamage ELISA kit (Cell Biolabs Inc., San Diego, CA, USA) according to the manufacturer's instruction.
Statistical analysis
Each experiment was repeated for at least three times. Quantitative data were expressed as the mean ± s.e. Group data were analyzed by one-way analysis of variance. A value of Po0.05 was considered statistically significant. 
